COMBINATIONS OF ANTIBODIES SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND OTHER THERAPEUTIC AGENTS

An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, ar...

Full description

Saved in:
Bibliographic Details
Main Authors KOOPMAN, WILLIAM, J, ICHIKAWA, KIMIHISA, ZHOU, TONG, OSHUMI, JUN, KIMBERLY, ROBERT, P, LOBUGLIO, ALBERT, F, BUCHSBAUM, DONALD, J
Format Patent
LanguageEnglish
French
Published 08.05.2003
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth. L'invention porte sur un anticorps ayant une interaction avec le récepteur DR5 ou DR4 humain et générant des effets agonistes ou antagonistes en aval du récepteur, cet anticorps permettant d'inhiber la prolifération cellulaire et l'apoptose. L'invention porte également sur des procédés de production et d'utilisation des anticorps, éventuellement en combinaison avec divers agents thérapeutiques, notamment dans le traitement de maladies relatives à l'apoptose et de la prolifération cellulaire anarchique.
Bibliography:Application Number: WO2002US34420